Catalyst Wire Dossier Catalyst Wire Dossier

Lebrikizumab (LY3650150)

Lebrikizumab · Eli Lilly and Company
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Lebrikizumab (LY3650150), covering 2025-06-11 to 2026-04-20. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) [Phase 3]

See pricing